Randomized trial demonstrates reduced fracture risk in postmenopausal osteoporosis, indicating zoledronic acid provides effective long-term bone protection.
A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
No takes yet. Share an insight, caveat, or question.
Black et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: